VAXIMM is primarily focused on developing active immunotherapies for patients suffering from cancer. The company’s initial product candidate VXM01 is targeting the tumor vasculature, which is essential for tumors to grow beyond microscopic size. VAXIMM was formed in 2008 as a joint venture of BB Biotech Ventures and Merck KGaA, Darmstadt, Germany.